Literature DB >> 29755835

Trisomy 6 as the sole stemline abnormality in a patient with acute monocytic leukemia: a case report.

Masahiro Manabe1, Reiko Asada2, Yuji Hagiwara2, Dai Momose1, Yasuyoshi Sugano1, Takeshi Mazaki3, Ki-Ryang Koh1.   

Abstract

It is rare for trisomy 6 to occur as the sole autosomal anomaly in hematological malignancies, but this finding has been reported to be associated with a hypoplastic bone marrow. We report the case of a 75-year-old male with acute monocytic leukemia, in which trisomy 6 was detected as the sole stemline abnormality. We also summarize the 26 published cases of acute myeloid leukemia involving isolated trisomy 6.

Entities:  

Keywords:  Acute myeloid leukemia; hyperplastic bone marrow; trisomy 6

Year:  2018        PMID： 29755835      PMCID： PMC5943614     

Source DB:  PubMed          Journal:  Am J Blood Res        ISSN： 2160-1992


  17 in total

1.  Primary, single, autosomal trisomies associated with haematological disorders. United Kingdom Cancer Cytogenetics Group (UKCCG).

Authors: 
Journal:  Leuk Res       Date:  1992-09       Impact factor: 3.156

2.  Systematic screening at diagnosis of -5/del(5)(q31), -7, or chromosome 8 aneuploidy by interphase fluorescence in situ hybridization in 110 acute myelocytic leukemia and high-risk myelodysplastic syndrome patients: concordances and discrepancies with conventional cytogenetics.

Authors:  Valérie Beyer; Chantal Castagné; Dominique Mühlematter; Valérie Parlier; Jürg Gmür; Urs Hess; Tibor Kovacsovics; Sandrine Meyer-Monard; André Tichelli; Andreas Tobler; Emanuel Jacky; Urs Schanz; Mario Bargetzi; Anne Hagemeijer; Theo de Witte; Guy van Melle; Martine Jotterand
Journal:  Cancer Genet Cytogenet       Date:  2004-07-01

3.  Trisomy 6 in a child with acute megakaryoblastic leukemia (AML-M7).

Authors:  Simon J McCullough; Michael J Neat; Maryse Power; Aengus O'marcaigh
Journal:  Cancer Genet Cytogenet       Date:  2004-10-15

4.  Comparative genomic hybridization and conventional cytogenetic analyses in childhood acute myeloid leukemia.

Authors:  T Huhta; K Vettenranta; K Heinonen; J Kanerva; M L Larramendy; E Mahlamäki; U M Saarinen-Pihkala; S Knuutila
Journal:  Leuk Lymphoma       Date:  1999-10

5.  Chromosomal alterations associated with evolution from myelodysplastic syndrome to acute myeloid leukemia.

Authors:  T de Souza Fernandez; M H Ornellas; L Otero de Carvalho; D Tabak; E Abdelhay
Journal:  Leuk Res       Date:  2000-10       Impact factor: 3.156

Review 6.  Trisomy 6 as a primary karyotypic aberration in hematologic disorders.

Authors:  A N Mohamed; M L Varterasian; S M Dobin; T S McConnell; S R Wolman; C Rankin; C L Willman; D R Head; M L Slovak
Journal:  Cancer Genet Cytogenet       Date:  1998-10-15

7.  Cytogenetic analysis of hematologic malignancies in Hong Kong. A study of 98 cases.

Authors:  L C Chan; Y L Kwong; H W Liu; T K Chan; D Todd; L M Ching
Journal:  Cancer Genet Cytogenet       Date:  1992-09

8.  Prognostic significance of chromosome analysis in de novo acute myeloid leukemia (AML).

Authors:  H J Weh; R Kuse; R Hoffmann; D Seeger; S Suciu; H Kabisch; J Ritter; D K Hossfeld
Journal:  Blut       Date:  1988-01

9.  Clinical significance of previously cryptic copy number alterations and loss of heterozygosity in pediatric acute myeloid leukemia and myelodysplastic syndrome determined using combined array comparative genomic hybridization plus single-nucleotide polymorphism microarray analyses.

Authors:  Kyung-Nam Koh; Jin Ok Lee; Eul Ju Seo; Seong Wook Lee; Jin Kyung Suh; Ho Joon Im; Jong Jin Seo
Journal:  J Korean Med Sci       Date:  2014-07-11       Impact factor: 2.153

10.  Sole Infrequent Karyotypic Aberration Trisomy 6 in a Patient with Acute Myeloid Leukemia and Breast Cancer in Remission.

Authors:  Mürüvvet Seda Aydın; Süreyya Bozkurt; Gürsel Güneş; Ümit Yavuz Malkan; Tuncay Aslan; Sezgin Etgül; Yahya Büyükaşık; İbrahim Celalettin Haznedaroğlu; Nilgün Sayınalp; Hakan Göker; Haluk Demiroğlu; Osman İlhami Özcebe; Salih Aksu
Journal:  Turk J Haematol       Date:  2016-11-22       Impact factor: 1.831
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.